Due to FDA regulations we cannot give specific advice on how to use CBD for a particular condition such as epilepsy. Fortunately though, the process to find a minimum effective dose of CBD for any condition, is very simple. The key to finding the most effective dosage is by using what is called, a Stepwise Dosing procedure.
It is important to note that CBD products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. We are restricted from making any claims about the efficacy of our specific CBD products to treat or cure any disease or medical condition including epilepsy.
The Stepwise Dosing Procedure
About Sleep: Often times, certain conditions or side-effects from medication can create insomnia. Sleep is essential to the bodies healing and recovery process. If sleep deprivation is an issue, you may want to consider weighting your dosage heavier at night to assist with a more sound sleep.
Many people do not like vaping so the choice to use a sublingual oil is easy. Others may choose a vapor product over a sublingual oil because of the higher absorption rate, faster onset and convenience of carrying it on your person. Some prefer the sublingual oils because the effects last longer, it is easier to dial-in an exact dosage, and easier to take higher dosage servings. Many customers will opt to do both, using the sublingual oil for the main dose and a vape pen to supplement between doses. This is especially helpful for people tackling anxiety or chronic pain who may need to supplement throughout the day.
6. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology. 2016;15(3):270-278.
This study showed that the addition of CBD to a traditional seizure medication decreased the frequency of drop seizures significantly in children and adults with LGS.
It is important to know that even though marijuana is a plant, it is broken down in a person’s liver like many medicines. People mistakenly believe that marijuana is completely safe because it is a plant or oil from a plant. However, medication interactions can occur.
When conventional treatments do not work to control seizures, as is the case for roughly 30% of people with epilepsy, it is not unreasonable to consider CBD oil. However, this should only be considered after a thorough evaluation at a specialized epilepsy center to look at whether all possible treatments (including FDA-approved new and add-on medicines, dietary therapy, devices, and surgery) have been reasonably tried.
Results from Gold Standard Studies of Epidiolex (CBD)
Studies in the U.S. of Epidiolex (a plant-based CBD formulation) have been ongoing for a number of years. Data from these studies has helped provide evidence that led to the FDA approval of this product on June 25, 2018.
The FDA approval and Drug Enforcement Administration (DEA) scheduling of Epidiolex brings to market the first plant-based drug derived from the cannabis plant in the U.S.
In this episode of Hallway Conversations, epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Dr. Jose Cavazos MD, PhD, professor of neurology at the University of Texas Health Science Center in San Antonio. They discuss Dr. Cavazos’ experience serving as a panelist on the recent U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drug Advisory Committee review of Epidiolex ® for the treatment of Dravet and Lennox-Gastaut syndromes.
This study was able to show that among people with the Dravet syndrome, CBD resulted in a greater decrease in convulsive-seizures than placebo. It also showed that CBD was associated with higher rates of adverse events.
fostamatinib will increase the level or effect of cannabidiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor.
cannabidiol will increase the level or effect of carvedilol by decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates.
Monitor Closely (1) cannabidiol, cyclobenzaprine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition with the coadministration of CYP1A2 substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate.
Monitor Closely (1) haloperidol will increase the level or effect of cannabidiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor.
Monitor Closely (1) cannabidiol will increase the level or effect of ketamine by decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates.